Suppr超能文献

O-RADS US v2022:美国放射学会卵巢-附件报告和数据系统美国委员会的更新。

O-RADS US v2022: An Update from the American College of Radiology's Ovarian-Adnexal Reporting and Data System US Committee.

机构信息

From the Department of Radiology and Biomedical Imaging and Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, 1001 Potrero Ave, 1X57, San Francisco, CA 94110 (L.M.S.); Department of Radiology, Stanford University School of Medicine, Palo Alto, Calif (P.J.); Department of Radiology and Radiologic Sciences, Vanderbilt University Medical Center, Nashville, Tenn (C.H.P.); Department of Obstetrics, Gynecology, and Reproductive Sciences, Larner College of Medicine at the University of Vermont, Burlington, Vt (M.M.B.P.); Department of Obstetrics and Gynecology, University Hospitals and Department of Development and Regeneration, KU Leuven, Leuven, Belgium (W.F., D.T.); Department of Medical Imaging, Sunnybrook Health Science Centre, University of Toronto, Toronto, Canada (P.G.); Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (Y.G.); Department of Radiology, Mayo Clinic Arizona, Phoenix, Ariz (M.D.P.); Department of Radiology, McGill University Health Centre, Montreal, Canada (C.R.); Department of Gynecologic Oncology, Kaiser Permanente Northern California, Walnut Creek, Calif (E.J.S.B.); and Department of Radiology and Radiological Sciences and Department of Obstetrics and Gynecology, Vanderbilt University College of Medicine, Nashville, Tenn (R.F.A.).

出版信息

Radiology. 2023 Sep;308(3):e230685. doi: 10.1148/radiol.230685.

Abstract

First published in 2019, the Ovarian-Adnexal Reporting and Data System (O-RADS) US provides a standardized lexicon for ovarian and adnexal lesions, enables stratification of these lesions with use of a numeric score based on morphologic features to indicate the risk of malignancy, and offers management guidance. This risk stratification system has subsequently been validated in retrospective studies and has yielded good interreader concordance, even with users of different levels of expertise. As use of the system increased, it was recognized that an update was needed to address certain clinical challenges, clarify recommendations, and incorporate emerging data from validation studies. Additional morphologic features that favor benignity, such as the bilocular feature for cysts without solid components and shadowing for solid lesions with smooth contours, were added to O-RADS US for optimal risk-appropriate scoring. As O-RADS US 4 has been shown to be an appropriate cutoff for malignancy, it is now recommended that lower-risk O-RADS US 3 lesions be followed with US if not excised. For solid lesions and cystic lesions with solid components, further characterization with MRI is now emphasized as a supplemental evaluation method, as MRI may provide higher specificity. This statement summarizes the updates to the governing concepts, lexicon terminology and assessment categories, and management recommendations found in the 2022 version of O-RADS US.

摘要

O-RADS US 于 2019 年首次发布,为卵巢和附件病变提供了标准化词汇,通过基于形态特征的数字评分对这些病变进行分层,以指示恶性风险,并提供管理指导。该风险分层系统随后在回顾性研究中得到验证,即使在不同专业水平的使用者中也具有良好的读者间一致性。随着该系统的使用增加,人们认识到需要更新以解决某些临床挑战,阐明建议,并纳入验证研究的新数据。O-RADS US 增加了一些支持良性的额外形态特征,例如无实性成分的囊肿的双腔特征和具有平滑轮廓的实性病变的阴影,以便对最佳风险进行适当评分。由于 O-RADS US 4 已被证明是恶性的适当截止值,因此现在建议对风险较低的 O-RADS US 3 病变进行超声随访,如果未切除的话。对于实性病变和含有实性成分的囊性病变,现在强调 MRI 作为补充评估方法进行进一步特征描述,因为 MRI 可能具有更高的特异性。本声明总结了 O-RADS US 2022 版中关于管理概念、词汇术语和评估类别以及管理建议的更新。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验